Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies

• Published in: Endocrine reviews Vol. 43; no. 6; pp. 1051 - 1073
• Main Authors: Lerario, Antonio Marcondes, Mohan, Dipika R, Hammer, Gary D
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01-12-2022
• Subjects: Adrenal cortex; Adrenal Cortex Neoplasms - drug therapy; Adrenal Cortex Neoplasms - genetics; Adrenal Glands; Adrenocortical Carcinoma - drug therapy; Adrenocortical Carcinoma - genetics; Biology; Cancer; Carcinoma; Catecholamines; Chemotherapy; Cytotoxicity; Development and progression; Epigenetic inheritance; Epigenetics; Genetic aspects; Genetic research; Genomes; Genomics; Health aspects; Homeostasis; Hormones; Humans; Medical research; Medicine, Experimental; Metastases; Metastasis; Mitotane - therapeutic use; Neuroendocrine tumors; Physiological aspects; Review; Steroid hormones; Tumors; Michigan; adrenocortical carcinoma; molecular biomarkers; genomics; adrenocortical development and homeostasis; targeted therapies
• ISSN: 0163-769X; 1945-7189
• DOI: 10.1210/endrev/bnac012

Abstract
The adrenal glands are paired endocrine organs that produce steroid hormones and catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal cancer of the peripheral domain of the gland, the adrenal cortex. Recent research in adrenal development, homeostasis, and disease have refined our understanding of the cellular and molecular programs controlling cortical growth and renewal, uncovering crucial clues into how physiologic programs are hijacked in early and late stages of malignant neoplasia. Alongside these studies, genome-wide approaches to examine adrenocortical tumors have transformed our understanding of ACC biology, and revealed that ACC is composed of distinct molecular subtypes associated with favorable, intermediate, and dismal clinical outcomes. The homogeneous transcriptional and epigenetic programs prevailing in each ACC subtype suggest likely susceptibility to any of a plethora of existing and novel targeted agents, with the caveat that therapeutic response may ultimately be limited by cancer cell plasticity. Despite enormous biomedical research advances in the last decade, the only potentially curative therapy for ACC to date is primary surgical resection, and up to 75% of patients will develop metastatic disease refractory to standard-of-care adjuvant mitotane and cytotoxic chemotherapy. A comprehensive, integrated, and current bench-to-bedside understanding of our field’s investigations into adrenocortical physiology and neoplasia is crucial to developing novel clinical tools and approaches to equip the one-in-a-million patient fighting this devastating disease.
Graphical Abstract
Graphical Abstract